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ABSTRACT
Objective: To  compare resources used in the medical
and laparoscopic treatment of unruptured ectopic preg-
nancy. 
Methods: We  prospectively recorded all the medical
resources required in the treatment of unruptured
ectopic pregnancy. The study period ranged from
January 1, 1995 to June 30, 1998. Single-dose intramus-
cular methotrexate injections were administered in 55
women (group I). This therapeutic option was provided
on an outpatient basis in small EP (β-HCG level < 5000
IU/L and hematosalpinx diameter < 3 cm). Serial clinical
controls and biologic tests were performed until bHCG
became negative. Forty women underwent a laparoscop-
ic salpingostomy because they refused the methotrexate
regimen or had “social” contra-indications (ie, pre-
dictable difficulties in the follow-up) (group II). Twenty-
one patients underwent conservative laparoscopic treat-
ment because of “medical” contraindications to
methotrexate (group III). We recorded the resources
used with the outpatient and inpatient treatment in each
group (methotrexate consumption, operating room acts,
length of hospital stay, clinical examinations, biological
tests, and sonograms during the follow-up). 
Results: We observed similar cure rates in each group,
but it took significantly longer for β-HCG to become neg-
ative in group 1. However, hospitalization was signifi-
cantly less often required, and the length of hospital stay
was shorter in this group. But length of follow-up, num-
ber of office visits, biological tests, sonograms, and sub-
sequent readmissions were significantly more frequent
after methotrexate. Despite more severe clinical presen-
INTRODUCTION
Today medical treatment of unruptured ectopic pregnan-
cy (unruptured EP) constitutes an accepted alternative to
laparoscopic salpingostomy.1 Randomized trials have
demonstrated similar efficacy for laparoscopy and
methotrexate either via intramuscular (IM),2 or intratubal
injection.3-5 Subsequent fertility also appears comparable
to that observed after conservative laparoscopy.5
Some works have considered the resources used and the
cost of EP treatments through simulations and retrospec-
tives studies.6-11 Methotrexate (MTX) appeared of interest
because it decreased the costs of EP management by up
to 48% when compared with laparoscopy.6,11 However,
the severity of EP treated by MTX or laparoscopy may be
quite different, and this difference could influence cost
calculations.
It seemed interesting to us to prospectively assess the
medical resources used by different approaches for con-
servative treatment of EP.
MATERIALS AND METHODS
The aim of this study was to compare the resources used
for the treatment of unruptured EP either by single-dose
IM MTX injections or conservative laparoscopy. We also
wanted to assess medical needs according to the initial
presentation of unruptured EP. The study period ranged
from January 1, 1995 to June 30, 1998. 
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tations for patients in group III, we didn’t find any sig-
nificant differences in the hospital resources used in this
group in comparison with those used in group II. 
Conclusions: The outpatient methotrexate option may
result in low consumption of resources for a hospital
because most of the follow-up can be performed by city
practitioners and laboratories. For the laparoscopic
option, efforts should be made to reduce the postopera-
tive hospital stay. 
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MTX was proposed for small unruptured EP in coopera-
tive patients living near our department (inclusion and
exclusion criteria are given in Table 1) (group I). This
was given on an outpatient basis via single IM injections
(1 mg/Kg) (Methotrexate, Ledertrexate, Léderlé, Paris,
France, 50 mg/ampoule) β-hCG assays were scheduled
on posttherapeutic days four and seven, and then once
weekly. Biologic tests were mostly performed in our hos-
pital laboratory. Sonograms were performed at the prac-
titioner’s request. A second injection was indicated when
β-hCG level did not decrease between two consecutive
assays.
Laparoscopic salpingostomy was performed in patients
who refused the protocol or who had the “medical” inclu-
sion criteria for MTX (group III). Salpingectomies were
not included in this study. We used the classic three-port
access with the patient under general anesthesia. Patients
were discharged on postoperative day two, as is usual in
France. β-hCG titre and CBC were assessed on day two.
Subsequently, β-hCG level was quantified weekly until
normalization. A second MTX injection (1 mg/kg) was
indicated for patients with stagnating β-hCG levels.
All the resources needed in each case have been
prospectively recorded. We took into account major
physicians or laboratory acts required by outpatient,
ambulatory, or inpatient management from presentation
to completion of follow-up (negative β-hCG assay in clin-
ically normal patients). This included MTX consumption,
blood transfusion, surgeon anesthetic acts, duration of
hospital stay, and posttherapeutic office visits, biological
tests (β-hCG assay, liver tests, CBC), and sonograms dur-
ing follow-up. The management of failures was included
in the calculation as well. Data relevant to clinical and
biologic results and the final evolution were prospec-
tively recorded by the patient’s referring physician in the
department. 
Statistical analysis used the ANOVA test, chi-square test,
or Pearson correlation coefficient and was carried out
with a statistical software program (SPSS 6.1, SPSS-
France, Boulogne, France).
RESULTS
One hundred twenty-two patients were treated conserv-
atively for unruptured EP during the study period. Fifty-
five women received IM MTX (group I), 40 had social
contraindications to MTX or refused the protocol (group
II), and 21 had medical contraindications to MTX (group
III). Six patients received MTX even though they did not
strictly fulfil the inclusion criteria. MTX was preferred in
these cases, with patients’ consent, because of severe
surgical or anesthetic risk factors. Patients stayed in the
department until the β-hCG level showed a significant
fall and were not included in this study. The three groups
were comparable for demographic features and gesta-
tional age at presentation. Conversely, the initial β-hCG
level and mean hematosalpinx diameter were significant-
ly higher in group III in contrast with those in group I or
II (Table 2) (groups I and II were comparable for those
criteria, P = 0.4). In group I, 48 women were cured with
a single injection (87%), four required a second injection,
and two subsequent injections were given in one 
case (total cure rate = 96%). Two patients underwent
laparoscopy during follow-up indicated by serious pelvic
pain in one case and a stagnant β-hCG level in the other.
We recorded one case of stomatitis as a complication and
no biological adverse effect in this group. In group II, 34
Table 1.
Selection of ectopic pregnancies for methotrexate therapy.
Inclusion criteria Exclusion criteria
β-hCG level < 5000 IU * L-1 Spontaneous pelvic pain
Hematosalpinx diameter < 3 cm on TVS Hemodynamic unstable 
Small amount of peritoneal fluid on TVS  Fetal cardiac activity
Acceptance of strict clinical and laboratory follow-up Evidence of hepatic or renal disease
Dwelling place close to the hospital
β-hCG=β-human chorionic gonadotropin; TVS=transvaginal sonography. JSLS(2001)5:117-122 119
Table 2.
Characteristics of groups I, II and II.*
Group I Group II Group III P
n = 55 n = 40 n = 21
Age (year) 30.8 +/- 5.5 29.3 +/- 5.2 28.4 +/- 5.7 0.2
0 or 1 Para 87.2% 74.3% 85.7% 0.1
History of EP 20% 12.5% 23.8% 0.3
hCG level at diagnosis (IU / L) 1286 +/- 1152 1513 +/- 1429 3363 +/- 2356  < 0.001
Hematosalpinx diameter (mm) 21 +/- 8.8 19.1 +/- 7.4 42.3 +/- 14.4 < 0.001
Gestational age at diagnosis (days) 41.3 +/- 11.7 43.9 +/- 13.3 36 +/- 14.3 0.3




Rate of hospitalization: 
Group I Group II Group III P
(n = 55) (n = 40) (n = 21)
Initial treatment
ambulatory 80% 0 0
outpatient 9% 0 0
inpatient 11% 100% 100% < 0.001
Subsequent Readmission 11% 2% 0 < 0.05
Mean length of hospital stay: 
Group I Group II Group III P
(n = 55) (n = 40) (n = 21)
Initial treatment 0.6 +/- 1.7 2.7 +/- 0.7  4.2 +/- 6.6 < 0.05
Subsequent Readmission 2 (1 - 2)  4 - < 0.05
Table 4.
Resources use.*
Group I  Group II  Group III P
(n = 55) (n = 40) (n = 21)
Blood Transfusion 0 0 0 -
Laparoscopy 2 42 21
Ampoules of MTX 2.2 +/- 0.7 (2-6) 0.2 +/- 0.6 (0-2) 0.2 +/- 0.7 (0-2) < 0.001
Office visits 2.4 +/- 1.4 (1-7) 1.01 +/- 1 (1-4) 1.4 +/- 1.2 < 0.001
hCG assays 4.6 +/- 2 (1-10) 2.6 +/- 1.7 (1-9) 2.5 +/- 1.5 < 0.001
CBC 2.7 +/- 1.1 (1-8) 1.2 +/- 0.9 (1-6) 0.9 +/- 0.5 < 0.001
Liver tests 2.2 +/- 1.2 (0-6) 0.15 +/- 0.4 (0-2) 0.15 +/- 0.4 (0-2) < 0.001
Sonograms 1 +/- 1 (0-4) 0.4 +/- 0.6 (0-3) 0.3 +/- 0.6 (0-3) < 0.01
*Results are expressed as mean of acts and standard deviation (range)
MTX=methotrexate; CBC=complete blood cell count.Hospital Resources Used for Ectopic Pregnancy Treatment by Laparoscopy and Methotrexate, Lecuru F et al.
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patients were cured after laparoscopy (85%) and five sub-
sequently required a methotrexate injection (1 mg/Kg)
for persistent EP. In addition, one patient underwent a
laparoscopic salpingectomy for persistent bleeding. In
Group III, 18 patients (86%) were cured with
laparoscopy, and three subsequently required one MTX
injection. The cure rates for the three approaches were
not significantly different (P = 0.7).
Resources needed for the three strategies are shown in
Tables 3 and  4. No blood transfusion was required.
Management has naturally been significantly different for
the two treatment options, with a high rate of outpatient
and ambulatory care in group I, whereas hospitalization
was constant in the other two groups (Table 3) (P <
0.001). Hospital stay was significantly longer in group II
and III (P < 0.05). Mean hospital stay was longer in group
III in comparison with that in group II, but the difference
here is not significant. On the other hand, subsequent
readmission to the hospital was significantly more fre-
quent in group I (11% vs 2% vs 0, P < 0.05). In addition,
follow-up was significantly longer in the MTX group (27.3
+/- 10.8 days) in comparison with that in group II (10.2
+/- 8.4) and III (8.7 +/- 8.2) (P < 0.05). Finally, office vis-
its, β-hCG assays, CBC, and liver tests were significantly
more numerous in this group (Table 3).
In terms of observed resources used, MTX resulted in a
low number of days in the hospital and in a high num-
ber of posttherapeutic laboratory tests and office visits.
Laparoscopy had the opposite characteristics.
DISCUSSION
Health technology assessment is now an important aspect
of analysis and planning of medical activities. Besides
weighing different surgical options, comparing surgical
and medical management is now gaining interest.12
Analysis of medical goods and service consumption con-
stitutes a part of this assessment that could help in deci-
sion making or planning of health structures. In this
study, we analyzed the resources used instead of cost
because reimbursement systems largely differ among
countries.
Unruptured EP treatment is an interesting topic because
it remains a frequent pathology in western countries,
leading to consistent medical activity.13,14 Most of the
diagnoses of EP are now performed at an early stage,
before life-threatening tubal rupture that is today an infre-
quent occurrence.10 Three treatments can be proposed
for unruptured EP in a modern algorithm: expectant
management, MTX injection, and laparoscopy.
Laparotomy is an invasive option that significantly
increases the cost of the treatment and should no longer
be indicated.15,16 In selected cases, MTX appears as effec-
tive as laparoscopy in terms of cure rate and subsequent
intrauterine pregnancy rate. Thus, systematic use of MTX
instead of laparoscopy for small EP could decrease
demands for medical resources. 
In this study, we assessed the resources required by MTX
and conservative laparoscopy in small and more
advanced EP. Because this study is not randomized,
potential bias could exist. In fact, patients in groups I and
II are comparable for clinical, sonographic, and biologic
criteria at presentation, and, in addition, demographic
features and medical history of those patients were not
significantly different (Table 2). Laparoscopy was per-
formed in women (group II) who refused MTX or didn’t
fulfil the conditions we required for the follow-up (com-
pliance, residency, for example). Conversely, group III
was constituted of patients who had more severe clinical
or biological characteristics. 
Our results are similar to those previously reported in
European countries for cure rates after laparoscopy,
length of hospitalization, and persistent EP rate after
laparoscopy.17
Finally, we selected parameters that are unquestionable
indicators of the consumption of medical goods and
services. 
MTX and laparoscopy differed quite considerably for
resource consumption. MTX resulted in a low rate of
hospitalization and a short hospital stay. Conversely, fol-
low-up after medical therapy was significantly longer
than after laparoscopy and required significantly more
office visits and biological tests. Laparoscopy provided
opposite issues: a long hospital stay and a short follow-
up requiring less physician time and biological tests.
Interestingly, groups II and III had similar outcomes in
terms of length of hospital stay and follow-up require-
ments, although clinical presentations differed greatly. 
It appears that the most logical indications for MTX are
EP, which can be treated on an out-patient basis, with a
short follow-up and a high success rate after one single
injection. Follow-up appears to be time-consuming for
physicians, patients, and laboratories. Surprisingly, fewstudies have addressed this topic.18 Establishing a more
rational protocol is of major interest, to provide sufficient
medical security for patients’ quality of life. Patients’
point of view should be better considered. It has been
reported that MTX could have a detrimental impact on
women’s health-related quality of life.19 The length of the
medical “pressure” and the repetition of tests could
explain that patients treated medically perceive them-
selves as unhealthy and alter their quality of life. 
In this series, MTX therapy led to a high rate of subse-
quent readmissions. They were most of the time related
to pelvic pain and were managed conservatively. But
they gave rise to consistent medical consumption in
terms of days of hospitalization and biological tests.
Efforts should be made to educate physicians and
patients to reduce the invasiveness of the management of
such predictable events. 
Laparoscopy resulted in a high number of days of 
hospitalization. It has been demonstrated that, hospital
charges constituted the main part of the direct cost.14
It is then logical that laparotomy generates higher costs
than laparoscopy, and that laparoscopy induces higher
costs than medical ambulatory treatments. It is now
demonstrated that single-dose MTX provides significant 
cost savings, when compared with conservative
laparoscopy.20,21 Efforts should, thus, be made to reduce
hospital stay after laparoscopic treatment of EP.
Outpatient surgery is an interesting alternative, but is not
a common policy in France today. Outpatient laparo-
scopic treatment of EP is feasible but it requires the
cooperation of the hospital with city practitioners, nurs-
es, and social workers.22 In our experience, most pro-
longed hospitalizations were not related to medical prob-
lems, but to unfavourable social situations (data not
shown). We wish to emphasise that to be really effective
and profitable reduction in the number of days of hospi-
tal stay should lead to the reduction in hospital beds at
patients’ disposal, allocating medical goods and assign-
ing health workers towards other activities, for example
cancer screening. 
This series confirms that the treatment of unruptured EP
with IM MTX gives similar results when compared with
laparoscopy. MTX therapy is simple and does not require
hospitalization, but follow-up is time-consuming and
requires a lot of biological tests. Today, this follow-up is
mainly carried out in the hospital, but this could be
achieved by local physicians and independent laborato-
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ries in the near future. Laparoscopy mainly consumes
resources during the hospital stay. Technical acts (anaes-
thesia and surgery) and hospital charges cannot be
avoided; however, the length of postoperative hospital
stay could be shortened. This may constitute a goal for
the future in France. 
References:
1. Tulandi T, Saleh A. Surgical management of ectopic preg-
nancy. Clin Obstet Gynecol. 1999;42:31-38. 
2. Hajenius PJ, Engelsbel S, Mol BW, et al. Randomised trial of
systemic methotrexate versus laparoscopic salpingostomy in
tubal pregnancy. Lancet. 1997;350(9080):774-779.
3. O’Shea RT, Thompson GR, Harding A. Intra-amniotic
methotrexate versus CO2 laser laparoscopic salpingotomy in the
management of tubal ectopic pregnancy - a prospective ran-
domized trial. Fertil Steril. 1994;62:876-878.
4. Fernandez H, Pauthier S, Doumerc S, et al. Ultrasound-guid-
ed injection of methotrexate versus laparoscopic salpingotomy in
ectopic pregnancy. Fertil Steril. 1995;63:25-29.
5. Fernandez H, Vincent Y, Pauthier S, Audibert F, Frydman R.
Randomized trial of conservative laparoscopic treatment and
methotrexate administration in ectopic pregnancy and subse-
quent fertility. Hum Reprod. 1998;13:3239-3343. 
6. Creinin M, Washington A. Cost of ectopic pregnancy manage-
ment: surgery versus methotrexate. Fertil Steril. 1993;60:963-969.
7. Alexander JM, Rouse DJ, Varner E, Varner E, Austin M.
Treatment of the small unruptured ectopic pregnancy: a cost
analysis of methotrexate versus laparoscopy. Obstet Gynecol.
1996;88:123-127.
8. Lécuru F, Taurelle R, Viens-Bitker C, Robin F. Cost of unrup-
tured ectopic pregnancy treatment: comparison of laparoscopy
and methotrexate injection. Gynaecol Endosc. 1996;5:25-28.
9. Yao M, Tulandi T, Kaplow M, Patch Smith A. A comparison
of methotrexate versus laparoscopic surgery for the treatment of
ectopic pregnancy: a cost analysis. Hum Reprod. 1996;11:2762-
2766.
10. Yao M, Tulandi T. Current status of surgical and non surgical
management of ectopic pregnancy. Fertil Steril. 1997;67:421-423.
11. Hidlebaugh D, O’Mara P. Clinical and financial analysis of
ectopic pregnancy management at large health plan. J Am Assoc
Gynecol Laparosc. 1997;4:207-213.
12. Reeves B. Health-technology assessment in surgery. Lancet.
1999;353(suppl):3-5.
13. Coste J, Job-Spira N, Aublet-Cuvelier B, et al. Incidence of
ectopic pregnancy. First results of a population-based register in
France. Hum Reprod. 1994;9:742-745.Hospital Resources Used for Ectopic Pregnancy Treatment by Laparoscopy and Methotrexate, Lecuru F et al.
122 JSLS(2001)5:117-122
14. Washington A, Katz P. Ectopic pregnancy in the United
States: economic consequences and payment source trends.
Obstet Gynecol. 1993;81:287-292.
15. Foulk RA, Steiger RM. Operative management of ectopic
pregnancy: a cost analysis. Am J Obstet Gynecol. 1996;175:90-96.
16. Lécuru F, Robin F, Taurelle R. Cost of the unruptured ectopic
pregnancy treatment: is there still a place for laparotomy? Am J
Obstet Gynecol. 1997;177:1275-1276.
17. Mol BWJ, Hajenius PJ, Engelsbel S, Ankum W, et al. Is con-
servative surgery for tubal pregnancy preferable to salpingecto-
my? An economic analysis. Br J Obstet Gynaecol. 1997;104:834-
839.
18. Brown D, Felker R, Stovall T, Emerson D, Ling W. Serial
endovaginal sonography of ectopic pregnancies treated with
methotrexate. Obstet Gynecol. 1991;77:406-409.
19. Nieuwerk PT, Hajenius PJ, Ankum WM, Van der Veen F,
Wijker W, Bossuyt P. Systemic methotrexate therapy versus
laparoscopic salpingostomy in patients with tubal pregnancy.
Part I. Impact on patient’s health related quality of life. Fertil
Steril. 1998;70:511-517.
20. Lécuru F, Robin F, Chasset S, Léonard F, Guitti S, Taurelle R.
Direct cost of single dose methotrexate for unruptured ectopic
pregnancy. Prospective comparison with laparoscopy. Eur J
Obstet Gynecol Biol Reprod. 2000;88:1-6.
21. Morlock RJ, Latafa JE, Eisenstein D. Cost-effectiveness of sin-
gle dose methotrexate compared with laparoscopic treatment of
ectopic pregnancy. Obstet Gynecol. 2000;95:407-412.
22. Learman L, Grimes D. Rapid hospital discharge following
laparoscopy for ectopic pregnancy: a promise unfulfilled? West J
Med. 1997;167:145-148.